In the fast-evolving world of nucleic acid therapies, precision, compliance, and speed are critical to success. Developers of mRNA and oligonucleotide therapies face intense pressure to deliver safe, effective treatments while navigating regulatory complexity and securing essential funding. A proven, phase-appropriate testing partner can make all the difference.

The Eurofins BioPharma Product Testing (BPT) network of laboratories offers comprehensive CMC testing services tailored for nucleic acid therapies, as APIs or biologics. With 10+ years of experience and more than 60 projects completed — including work on COVID-19 vaccines — our experts bring unrivalled insight and technical capability to your development programmes​ with comprehensive cGMP testing for:

We can support every stage of your product lifecycle with services including oligonucleotide characterisation, mRNA analysis, lipid nanoparticle (LNP) evaluation, and stability testing.

Our platform-based approaches, state-of-the-art instrumentation (including NGS and cell-based potency assays), experience with regulatory agency inspections, and phase-appropriate methodologies ensure you are positioned for success, not just in early discovery, but through scale-up, clinical trials, and regulatory filings.  

Recognising the importance of early GMP alignment, we work with developers to minimise the risk of costly rework or regulatory delays later.

Eurofins BPT offers flexible service models to meet accelerated timelines. No matter the geographic location, our local facilities provide redundancy and reliability to safeguard your critical milestones. 

For NAT developers, LNP manufacturers, and discovery companies focused on oligonucleotides and mRNA, we have become a proven CMC partner there to support you in innovation.